1. What should be done in terms of fertility preservation for patients with cancer? The French 2021 guidelines
- Author
-
Nathalie Rives, Blandine Courbière, Thierry Almont, Diana Kassab, Claire Berger, Michaël Grynberg, Aline Papaxanthos, Christine Decanter, Elisabeth Elefant, Nathalie Dhedin, Virginie Barraud-Lange, Marie-Christine Béranger, Charlotte Demoor-Goldschmidt, Nicollet Frédérique, Marianne Bergère, Lydie Gabrel, Marianne Duperray, Christine Vermel, Natalie Hoog-Labouret, Michèle Pibarot, Magali Provansal, Laurent Quéro, Hervé Lejeune, Charlotte Methorst, Jacqueline Saias, Jacqueline Véronique-Baudin, Sandrine Giscard d'Estaing, Fadila Farsi, Catherine Poirot, Éric Huyghe, UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), CHU Rouen, Normandie Université (NU), Institut méditerranéen de biodiversité et d'écologie marine et continentale (IMBE), Avignon Université (AU)-Aix Marseille Université (AMU)-Institut de recherche pour le développement [IRD] : UMR237-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM), CHU de la Martinique [Fort de France], Association Française d'Urologie, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Bordeaux [Bordeaux], CHU Lille, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hopital Saint-Louis [AP-HP] (AP-HP), Hôpital Cochin [AP-HP], Vice-Presidence, Association France Lymphome Espoir, Paris, Ile-de-France, France, Cancer and Radiation Team, INSERM UMRS 1018, Villejuif, France, Information and Promotion Department, Association Laurette Fugain, Paris, France, Agence de la biomédecine [Saint-Denis la Plaine], Institut National du Cancer [Boulogne Billancourt] (INC), Dispositif Spécifique Régional du Cancer ONCOPACA-CORSE (DSRC OncoPaca-Corse), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Hospices Civils de Lyon (HCL), Centre Hospitalier des Quatre Villes - Saint-Cloud (CHQV), Dispositif Spécifique Régional du Cancer ONCO AURA (DSR ONCO AURA), Développement Embryonnaire, Fertilité et Environnement (DEFE), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), National Cancer Institute, through CEO ruling No. 2021-01, dated 16/03/2021, Unicancer Group, Neuroendocrine, Endocrine and Germinal Differentiation Communication (NorDic), and Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Cryopreservation ,Male ,[SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health ,Cancer Research ,[SDV]Life Sciences [q-bio] ,Ovary ,Fertility Preservation ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics ,Practice guidelines ,Oncofertility ,Oncology ,Semen ,Neoplasms ,Humans ,Female ,France ,Supportive care - Abstract
International audience; Abstract Aim: To provide practice guidelines about fertility preservation (FP) in oncology. 93Methods: We selected 400 articles after a PubMed review of the literature (1987e2019). Recommendations: Any child, adolescent and adult of reproductive age should be informed about the risk of treatment gonadotoxicity. In women, systematically proposed FP counselling between 15 and 38 years of age in case of treatment including bifunctional alkylating agents, above 6 g/m2 cyclophosphamide equivalent dose (CED), and for radiation doses on the ovaries 3 Gy. For postmenarchal patients, oocyte cryopreservation after ovarian stimulation is the firstline FP technique. Ovarian tissue cryopreservation should be discussed as a first-line approach in case of treatment with a high gonadotoxic risk, when chemotherapy has already started and in urgent cases. Ovarian transposition is to be discussed prior to pelvic radiotherapy involving a high risk of premature ovarian failure. For prepubertal girls, ovarian tissue cryopreservation should be proposed in the case of treatment with a high gonadotoxic risk. In pubertal males, sperm cryopreservation must be systematically offered to any male who isto undergo cancer treatment, regardless of toxicity. Testicular tissue cryopreservation must be proposed in males unable to cryopreserve sperm who are to undergo a treatment with intermediate or severe risk of gonadotoxicity. In prepubertal boys, testicular tissue preservation is: - recommended for chemotherapy with a CED 7500 mg/m2 or radiotherapy 3 Gy on both testicles. - proposed for chemotherapy with a CED 5.000 mg/m2 or radiotherapy 2 Gy. If several possible strategies, the ultimate choice is made by the patient.
- Published
- 2022
- Full Text
- View/download PDF